HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at 2024 International Liver Congress

HighTide Therapeutics, Ltd., a clinical stage biopharmaceutical company, announced the presentation of multiple analyses from its Phase 2a study of Berberine Ursodeoxycholate (HTD1801) at the European Association for the Study of the Liver (EASL) Congress in Milan, Italy. The study focuses on patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM).

Dr. Leigh MacConell, Chief Development Officer of HighTide, highlighted the potential benefits of HTD1801 for patients with MASH and T2DM. The ongoing multi-regional Phase 2b study, CENTRICITY, is fully enrolled, with results expected in the first half of 2025.

Analyses presented included comparisons between HTD1801 and GLP-1 Receptor Agonists, showcasing HTD1801's superior benefits across cardiometabolic endpoints. Another analysis demonstrated HTD1801's ability to improve insulin sensitivity, providing a unique therapeutic approach for severe insulin resistance.

A study on gastrointestinal adverse events indicated that while mild to moderate events like diarrhea and nausea were common, their incidence decreased over time, supporting HTD1801's potential for long-term use in treating chronic diseases.